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Background: CRISPR-based diagnostics are a new class of highly sensitive and specific assays with multiple
applications in infectious disease diagnosis. SHERLOCK, or Specific High-Sensitivity Enzymatic Reporter
UnLOCKing, is one such CRISPR-based diagnostic that combines recombinase polymerase pre-amplification,
CRISPR-RNA base-pairing, and LwCas13a activity for nucleic acid detection.
Methods: We developed SHERLOCK assays capable of detecting all Plasmodium species known to cause
human malaria and species-specific detection of P. vivax and P. falciparum, the species responsible for the
majority of malaria cases worldwide. We further tested these assays using a diverse panel of clinical samples
from the Democratic Republic of the Congo, Uganda, and Thailand and pools of Anopheles mosquitoes from
Thailand. In addition, we developed a prototype SHERLOCK assay capable of detecting the dihydropteroate
synthetase (dhps) single nucleotide variant A581G associated with P. falciparum sulfadoxine resistance.
Findings: The suite of Plasmodium assays achieved analytical sensitivities ranging from 25-188 parasites per
reaction when tested against laboratory strain genomic DNA. When compared to real-time PCR, the P. falcipa-
rum assay achieved 94% sensitivity and 94% specificity during testing of 123 clinical samples. Compared to
amplicon-based deep sequencing, the dhps SHERLOCK assay achieved 73% sensitivity and 100% specificity
when applied to a panel of 43 clinical samples, with false-negative calls only at lower parasite densities.
Interpretation: These novel SHERLOCK assays demonstrate the versatility of CRISPR-based diagnostics and
their potential as a new generation of molecular tools for malaria diagnosis and surveillance.
Funding: National Institutes of Health (T32GM007092, R21AI148579, K24AI134990, R01AI121558,
UL1TR002489, P30CA016086)
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Timely and accurate diagnosis is an important component of
malaria control and elimination efforts. The current generation of
rapid diagnostic tests (RDTs) that detect Plasmodium falciparum histi-
dine-rich protein 2 (PfHRP2) are widely deployed, accounting for 74%
of all malaria testing in Africa in 2015, but they have shortcomings(https://www.who.int/malaria/publications/world-malaria-report-
2016/report/en/). Conventional PfHRP2-based RDTs only detect P. fal-
ciparum and miss low density infections, under approximately 200
parasites/mL. Because PfHRP2 antigenemia can persist for weeks,
they can produce false-positive results well after resolution of infec-
tion [1]. Additionally, increasing reports of false-negative RDT results
due to P. falciparum parasites that escape detection due to deletion
mutations of the pfhrp2 and pfhrp3 genes raise concern that PfHRP2-
based RDTs may be threatened in select regions of Africa (https://
www.who.int/malaria/publications/atoz/information-note-hrp2-
based-rdt/en/) [2]. While microscopy is the traditional gold-standard
Research in context
Evidence before this study
CRISPR-based diagnostics are a new family of assays that com-
bine the base-pairing recognition of CRISPR RNAs with the var-
ied function of Cas effector proteins to detect nucleic acid
targets with high sensitivity and specificity. SHERLOCK, or Spe-
cific High-Sensitivity Enzymatic Reporter UnLOCKing, is one of
two major classes of CRISPR-based diagnostics. The initial man-
uscript characterizing SHERLOCK described it as capable of
detecting DNA and RNA from pathogens at attomolar concen-
trations and detecting single nucleotide variants conferring
antimicrobial resistance. We identified 20 publications describ-
ing the use of SHERLOCK for molecular diagnosis in PubMed as
of January 19, 2021 (search terms: “SHERLOCK CRISPR” and
“Cas13a”). The majority involved assays for viral targets includ-
ing SARS-CoV-2, but proof-of-principle assays for human geno-
typing and species identification of fish were also described.
One manuscript published during review applied a CRISPR-
based diagnostic approach to Plasmodium spp. detection and
species differentiation using Cas12a.
The majority of malaria diagnostic testing worldwide relies
upon rapid diagnostic tests (RDTs) that detect parasite antigens.
Widely deployed malaria RDTs fail to detect low density infec-
tions, especially in non-falciparum infections, and Plasmodium
falciparum parasites with deletions of the P. falciparum histi-
dine-rich protein 2 and/or 3 genes. Parasites with these deletion
mutations have now been reported in at least 24 countries
worldwide, leading to renewed calls for new malaria diagnostic
approaches.
Added value of this study
We developed novel proof-of-concept SHERLOCK assays for
malaria that are capable of robust detection, species identifica-
tion, and drug-resistance genotyping of Plasmodium spp. We
validated these assays using diverse clinical samples collected
in Africa and Asia. This is one of the first manuscripts describing
the SHERLOCK method outside of its original group of authors
and is its first use for a eukaryotic pathogen in a large cohort of
human clinical samples. We demonstrate SHERLOCK’s potential
as a sensitive and specific diagnostic for malaria and its versatil-
ity for a range of applications.
Implications of all the available evidence
This manuscript demonstrates that SHERLOCK is a sensitive,
specific, and highly adaptable nucleic acid detection platform
that can be applied for a variety of uses in infectious disease
detection and drug resistance surveillance. While additional
streamlining and optimization is needed for field-ready imple-
mentation, the novel assays described herein have potential as
a new generation of malaria diagnostics.
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much of Africa because performance is highly operator dependent, it
is labor-intensive, and it requires careful, sustained training of per-
sonnel. RDTs that detect alternative antigens such as parasite lactate
dehydrogenase (pLDH) are less sensitive and heat-stable.
To address the shortcomings of antigen and microscopy-based
diagnostics, molecular methods have been developed to detect para-
site nucleic acid such as polymerase chain reaction (PCR), loop-medi-
ated isothermal amplification (LAMP), and recombinase polymerase
amplification (RPA) [35]. These modalities have proven themselves
highly sensitive and specific and can detect different Plasmodiumspecies and single nucleotide variants (SNVs), making it possible to
monitor the emergence and spread of drug resistance in a timely
manner [68]. However, most molecular methods have important
shortcomings, including relatively expensive instrument require-
ments and reagent costs. To overcome these challenges, a new gener-
ation of field-deployable malaria diagnostics capable of detecting
diverse species and drug-resistant variants is needed.
SHERLOCK is a CRISPR-based diagnostic that combines RPA, in
vitro transcription, and RNA target detection using custom-designed
CRISPR RNA (crRNA) oligonucleotides and Cas13a derived from the
bacteria Leptotrichia wadei (LwCas13a) (Figure 1) [9]. Briefly, the first
step of SHERLOCK is an RPA reaction performed with primers tagged
with a T7 promoter sequence to generate short, double-stranded
DNA (dsDNA) amplicons of a target sequence. In vitro transcription of
the RPA product by T7 polymerase produces single-stranded (ssRNA)
targets, which are recognized by base-pairing interactions with
LwCas13a:crRNA complex. CrRNA-ssRNA target base-pairing interac-
tions activate collateral RNAse activity of LwCas13a, which cleaves
fluorescent or colorimetric RNA reporter molecules in the reaction to
produce a detectable signal. SHERLOCK can also detect SNVs; crRNA-
ssRNA target base-pairing interactions are perturbed by mismatches
in the target region, leading to differential LwCas13a activation
depending on the presence or absence of a variant (Figure 2). Reac-
tion components can be combined into either one or two reactions,
with detection on a simple fluorimeter, lateral flow strip, or gold
nanoparticle-based colorimetry [10,11]. The range of potential appli-
cations for SHERLOCK is broad; reported applications include distin-
guishing Zika and dengue virus strains, genotyping human cancers
and transgenic rice, detecting antimicrobial resistance SNVs, and
detecting several agricultural viruses as well as the SARS-CoV-2 coro-
navirus (https://doi.org/10.1101/2020.05.04.20091231) [9-13].
Here, we describe novel proof-of-concept SHERLOCK assays that
enable robust detection of all five Plasmodium species known to be
pathogenic to humans and species-specific detection of the primary
causes of human disease P. falciparum and P. vivax. We apply these
assays to a panel of laboratory parasite strains, diverse clinical iso-
lates from Africa and Asia, and pools of Anopheles mosquitoes col-
lected in the field. We then describe an assay for detection of the
A581G SNV in the P. falciparum dihydropteroate synthase (dhps) gene
associated with resistance to sulfadoxine, one of the two components
of the primary antimalarial medication used in intermittent preven-
tive treatment of malaria in pregnancy (IPTp) throughout Africa [14].
While further optimization and streamlining is necessary before
these assays can be used clinically, we demonstrate the potential of
SHERLOCK-based diagnostics for the detection of malaria and other
human pathogens.
2. Materials and methods
2.1. RPA primer design
We designed RPA primers capable of genus-specific amplification
of the Plasmodium 18S ribosomal RNA gene, building upon existing
TaqMan real-time PCR assays [3]. PCR primers were extended to 30-
35 nt in length and modified to include nucleotide favorability crite-
ria described in the TwistAmp Assay Design Manual (https://www.
twistdx.co.uk/docs/default-source/RPA-assay-design/twistamp-
assay-design-manual-v2-5.pdf?sfvrsn=29). These RPA primers target
regions of the 18S rRNA gene that are conserved across human-
infecting Plasmodium species, allowing “plug and play” crRNA design
for species identification during the crRNA:LwCas13a base-pairing
step of SHERLOCK. RPA primers for the dhps SNV-detection SHER-
LOCK assays were designed using NCBI Primer Basic Local Alignment
Search Tool (BLAST) (RRID:SCR_004870) with default parameters and
the following modifications: amplicon size 100-140 nt, melting tem-
peratures between 54-67°C, and length between 30 and 35
Fig. 1. SHERLOCK reaction workflow. (A) DNA extracted from a patient with malaria or infected mosquito is subjected to (B) RPA including T7 promoter-tagged primers for amplifi-
cation of the Plasmodium 18S rRNA or P. falciparum dhps genes, followed by (C) IVT and LwCas13a:crRNA complex binding to genus-, species-, or genotype-specific target RNA. This
binding triggers collateral (D) activation of LwCas13a RNAse activity and cleavage of reporter RNA, separating the fluorescent reporter from its quencher and producing a signal.
Abbreviations: RPA, recombinase polymerase amplification; IVT, in vitro transcription; R, reporter; Q, quencher.
Fig. 2. SHERLOCK is capable of distinguishing the dhps A581G SNV associated with antimalarial drug resistance. Engineered target-crRNA mismatches produce differential Cas13a
activation and fluorescence output.
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TAATACGACTCACTATAGGG-3’) to the 5’ end of one RPA primer in
each set to enable in vitro transcription by T7 polymerase during the
LwCas13a detection step. All primers with off-target complementar-
ity predicted by BLAST were excluded. Salt-free primers were synthe-
sized by Integrated DNA Technologies (Coralville, Indiana). The full
list of oligonucleotides designed and used in this manuscript can be
found in Supplementary Table 1.
2.2. crRNA design
Oligonucleotides for crRNA synthesis were designed as two com-
plementary ssDNA oligonucleotides and then in vitro transcribed to
produce single-stranded 67 nt crRNAs. Each ssDNA oligonucleotide
was composed of three parts: a variable spacer region (to facilitate
recognition of the RNA target molecule), a constant region (to facili-
tate crRNA association with LwCas13a), and a T7 promoter sequence
(to facilitate crRNA in vitro transcription).
Spacers are 28 nt long and recognize the in vitro transcribed RNA
product of the RPA reaction through complementary base-pairing
[9]. For the P. falciparum and P. vivax species-specific SHERLOCK
assays, spacers were designed to bind a species-specific region of the
18S rRNA gene previously targeted for amplification during real-time
PCR assays [3]. Spacers were selected to have at least three mis-
matches between species for the P. falciparum and P. vivax-specific
assays to minimize off-target activity. For the pan-Plasmodium SHER-
LOCK assay, a spacer was selected in a region of the 18S rRNA gene
conserved between Plasmodium species.
Spacers for dhps SHERLOCK assays were designed to maximize the
difference in signal between a specific SNV and alternate motifs as
previously described [9]. To accomplish this, spacers were designedso the SNV is recognized at position 3 or 6, and a synthetic mismatch
between the spacer and target was present at position 5 or 4, respec-
tively (Supplementary Table 2). The resulting spacer has one mis-
match with the SNV of interest and two mismatches with the
alternate variant, producing a measurable difference in signal
between the two variants (Figure 2). Spacers were queried through
BLAST to search for any off-target complementarity [15].
The same constant LwCas13a-associating region was used as
described in Gootenberg et al. (2017), 5’-GGGGAUUUAGACUACCC-
CAAAAACGAAGGGGACUAAAAC-3’, and the T7 promoter sequence
used was 5’-GAAATTAATACGACTCACTATAGGG-3’ [9]. Put
together, two 89 nt ssDNA oligonucleotides (appended to spacer
sequences) for each crRNA were designed in the format 5’-
GAAATTAATACGACTCACTATAGGGGATTTAGACTACCCCAAAAAC-
GAAGGGGACTAAAAC-spacer-3’ and 5’-spacer reverse comple-
ment-GTTTTAGTCCCCTTCGTTTTTGGGGTAGTCTAAATCCCCTATAGT-
GAGTCGTATTAATTTC-3’. These oligonucleotides were ordered
from Integrated DNA Technologies (Coralville, IA). For each SHER-
LOCK assay, multiple crRNA designs were screened, and crRNAs
with the greatest signal:background and/or SNV signal:alternate
signal were selected for all future experiments (Supplemental
Figures 1-3).
2.3. crRNA synthesis
Complementary ssDNA oligonucleotides were annealed (final
concentration 10 mM each) in 10 mM TrisHCl, 50 mM KCl, and
1¢5 mMMgCl2 pH 8¢3 for 5 minutes at 95°C followed by a 5°C/minute
temperature decrease to 25°C. Annealed dsDNA templates were then
in vitro transcribed using the HiScribe T7 Quick High Yield RNA Syn-
thesis Kit (New England Biolabs, Ipswich, MA) using overnight
4 C.H. Cunningham et al. / EBioMedicine 68 (2021) 103415incubation as described in the protocol for <0¢3kb transcripts
(https://www.neb.com/products/e2050-hiscribe-t7-quick-high-
yield-rna-synthesis-kit#Protocols,%20Manuals%20&%20Usage).
CrRNAs were purified using RNAClean XP magnetic bead purification
(Beckman Coulter, Indianapolis, IN) and quantified by NanoDrop
spectrophotometry (ThermoFisher, Waltham, MA).
2.4. LwCas13a synthesis and purification
LwCas13a protein was synthesized and purified at the University
of North Carolina at Chapel Hill (UNC) Protein Expression and Purifi-
cation Core as previously described with several modifications [9].
Briefly, the pET His6-TwinStrep-SUMO-LwCas13a (NovoPro, Shang-
hai, China) expression vector was transformed into RosettaTM 2 (DE3)
pLysS Singles Competent Competent Cells (Millipore) in autoinduc-
tion media and grown at 37°C until OD=0¢6, when the temperature
was lowered to 18°C and grown overnight. The pellet was harvested
and stored at -80°C until purification. For purification, the pellet was
resuspended in lysis buffer (50 mM NaPO4, 500 mM NaCl, 20 mM
Imidazole, 1 mM PMSF, 50 mg/mL lysozyme) and mixed at 4°C for
30 min. The solution was then sonicated on ice and centrifuged for
1 hour at 10,000 x g at 4°C. Clarified supernatant was filtered using a
0¢45 micron filter. Filtered supernatant was then loaded over Nickel
Sepharose 6 Fast Flow resin (GE). The column was washed with 5 CV
Buffer A (50 mM NaPO4, 500 mM NaCl, 20 mM imidazole) and eluted
with 10 CV Buffer B (50 mM NaPO4, 500 mM NaCl, 500 mM imidaz-
ole). Buffer exchange was performed via dialysis to a final solution of
600 mM NaCl, 50 mM Tris-HCl pH 7¢5, 5% glycerol, and 2mM DTT.
2.5. Recombinase polymerase amplification
RPA reactions were conducted as described in TwistAmp Basic
Instruction Manual (TwistDx, Cambridge, UK) with several modifica-
tions (https://www.twistdx.co.uk/en/products/product/twistamp-
basic). Each 50 mL TwistAmp reaction was subdivided by first creat-
ing a 45 mL mastermix and aliquoting five 5 £ 9 mL reactions before
adding 1 mL of sample input. Magnesium acetate was added to the
mastermix before adding the sample input. To simulate human back-
ground in clinical samples, 40 ng human gDNA from buffy coat
(Sigma Aldrich, St. Louis, MO) was added in all experiments except
those using clinical isolates. RPA reactions were incubated at 37°C for
30 minutes in a thermal cycler with a 40°C heated lid. After the first 4
minutes of incubation, samples were removed, vortexed briefly, and
then returned to the thermal cycler for the remainder of the incuba-
tion period.
2.6. Detection using LwCas13a
LwCas13a detection reactions were performed as previously
described with several modifications. We chose LwCas13a rather
than Leptotrichia shahii Cas13a because LwCas13a has been demon-
strated to have higher RNA-guided RNase activity than LsCas13a and
is better characterized in the context of SHERLOCK assays [11]. Each
reaction was performed using 25 mL total volume and contained
45 nM LwCas13, 100-500 ng crRNA, 125 nM fluorescent RNA reporter
(RNAse Alert v2, ThermoFisher), 0¢625 mL murine RNase inhibitor
(New England Biolabs), 31¢25 ng background RNA (isolated from Bur-
kitt's Lymphoma (Raji), ThermoFisher), 1 mM rNTP mix (New Eng-
land Biolabs), 0¢75 mL T7 polymerase (New England Biolabs), 3mM
MgCl2, and 1¢25 uL of RPA product in nuclease assay buffer (20 mM
HEPES, 60 mM NaCl, 6 mM MgCl2, pH 6¢8) [10]. Detection reactions
were conducted in 96-well black half-area microplates (PerkinElmer,
Waltham, MA) and sealed with MicroAmp optical adhesive film
(ThermoFisher). Detection reactions were incubated for 3 hours at
37°C on a VICTOR Nivo fluorescent plate reader (PerkinElmer) with
fluorescence measurements taken every 5 minutes. Backgroundsubtracted fluorescence for each sample was calculated by subtract-
ing the average fluorescence intensity of the human gDNA controls at
180 minutes of the human gDNA control from each sample.
2.7. Analytical sensitivity and specificity estimation
To determine the analytical sensitivity of the SHERLOCK assays,
we performed each assay in triplicate using serially diluted template
DNA from P. falciparum strain Dd2 (MRA-150G) for P. falciparum, P.
vivax 18S rRNA plasmid DNA (MRA-178), P. ovale 18S rRNA plasmid
DNA (MRA-180), P. malariae 18S rRNA plasmid DNA (MRA-179), and
P. knowlesi genomic DNA (MRA-456G) (Bei Resources, Manassas,
VA). To facilitate ease of interpretation, we assumed six copies of 18S
rRNA targets per genome when calculating parasite genome-equiva-
lents [16]. Parasite DNA ranging from 105 and 102 parasite
genomes/mL was used to simulate expected parasite densities
observed during human infection, including clinical malaria (typically
102 to 105 parasites/mL) and subclinical infection. Differences in
mean background-subtracted fluorescence were assessed using the
student’s unpaired t-test. We then performed additional biological
replicates using 2-fold serial dilutions near the observed limit of
detection to improve the precision of our analytical sensitivity esti-
mates. Positive SHERLOCK calls were made if background-subtracted
fluorescence was positive. Finally, we assessed each assay’s analytical
specificity using high-concentration DNA for all human-infecting
Plasmodium species, including gDNA and 18S rRNA plasmid DNA as
described above and containing 100,000 parasite genome-equiva-
lents per microliter.
2.8. Clinical sensitivity and specificity estimation
We assessed the clinical sensitivity and specificity of our assays
using a panel of dried blood spot (DBS) samples collected in the Dem-
ocratic Republic of the Congo (DRC), Uganda, and Thailand. Samples
were chosen out of convenience; a summary of the sources of clinical
samples is provided in Supplementary Table 3. DRC samples were
collected from subjects presenting to government health facilities
with symptoms of malaria in Kinshasa, South Kivu, and Bas-Uele
Provinces in 2017 as part of a separate study of malaria rapid diag-
nostic test performance [17]. Ugandan samples were collected from
febrile children presenting to public health facilities located in the
Kasese District of western Uganda over the period November 2017 to
June 2018 [18]. Thai samples were collected from patients presenting
to public health clinics and found to be smear-positive for P. vivax
and as part of ongoing entomological surveillance in the Mae Sod dis-
trict of Tak Province, northwest Thailand in 2010. All enrolled sub-
jects provided informed consent. Ethical approvals were obtained by
the Kinshasa School of Public Health, Mbarara University of Science
and Technology, Uganda National Council for Science and Technol-
ogy, Walter Reed Army Institute of Research, Ministry of Public
Health in Thailand, and the University of North Carolina at Chapel
Hill.
The presence and species of Plasmodium in each sample was
determined using real-time PCR. Prior to DNA extraction, DBS were
stored at -20 or -80°C in sealed plastic bags with desiccant. Briefly,
DNA was extracted from three 6 mm DBS punches using Chelex-100
and saponin for DRC samples [19] Chelex-100 and Tween for Uganda
samples [20], and the QIAamp DNA mini kit (QIAGEN, Hilden, Ger-
many) for Thailand samples prior to storage at -20°C. DRC samples
were first subjected to a pan-Plasmodium real-time PCR assay target-
ing the 18S rRNA gene [21]. Positive samples were then subjected to
four species-specific, semi-quantitative 18S rRNA real-time PCR
assays for P. falciparum,[22] P. ovale,[23] P. malariae,[22] and P. vivax,
[24] respectively. Parasite densities for all DRC and Uganda samples
were determined using quantitative real-time PCR (qPCR) targeting
the single-copy P. falciparum lactate dehydrogenase (pfldh) gene as
C.H. Cunningham et al. / EBioMedicine 68 (2021) 103415 5previously described [25,26]. P. vivax infection was diagnosed and
parasite densities determined in Thailand using microscopy at the
time of DBS collection and later confirmed using qualitative, species-
specific 18S rRNA real-time PCR for P. vivax [22,24]. PCR primers,
probes, and reaction conditions are described in the Supplementary
File.
We first assessed the performance of all three assays using a panel
of 11 DNA samples from real-time PCR-confirmed Plasmodium infec-
tions, including the four major human species (no P. knowlesi clinical
isolates were available) and a range of parasite densities. We further
characterized the performance of the P. falciparum assay using a
panel of 62 PCR-positive and 50 PCR-negative samples collected in
the DRC and Uganda. Plasmodium SHERLOCK assays were performed
in triplicate for the panel of 11 DNA samples and once for the 112
samples collected in the DRC and Uganda. To improve specificity,
positive SHERLOCK calls were made if the absolute fluorescence was
at least 20% above background fluorescence. Clinical sensitivity, clini-
cal specificity, and Cohen’s Kappa coefficient were calculated using
real-time PCR as the gold standard.
2.9. Parasite DNA detection in mosquito pools using SHERLOCK
Parasite DNA was extracted from insectary-reared Anopheles dirus
mosquitoes fed on blood from gametocytemic P. falciparum-infected
volunteers in Cambodia. Mosquitoes were saved 9 and 16 days post-
feeding to capture oocyst-stage and sporozoite-stage infection,
respectively. They were pooled in groups of 10 and preserved in 95%
ethanol before undergoing DNA extraction via a simplified Chelex
protocol as previously described [27]. SHERLOCK assays were per-
formed on DNA from mosquito pools in triplicate. Comparison of
mean background-subtracted fluorescence values was performed
using the t-test as described above.
2.10. Deep sequencing of clinical samples and dhps genotyping
We selected 463 DNA samples from the DRC with P. falciparum
mono-infection by real-time PCR for dhps genotyping using a multi-
plex real-time PCR assay that discriminates wild-type from 581G
mutants (see Supplementary File for details) [7]. We then selected
samples for amplicon-based deep sequencing, including a subset of
92 wild-type and 581G mutant DNA samples identified during dhps
real-time PCR screening of DRC samples and 92 P. falciparum histi-
dine-rich protein 2-based RDT-positive samples from Uganda. Each
of these 184 samples was amplified using a barcode-labeled forward
and reverse primer (Supplementary Table 4). PCR reactions were car-
ried out in a total volume of 50 mL and using 5 mL of input DNA. The
reaction mixture contained 1X Accuprime PCR buffer II (Invitrogen,
Carlsbad, CA), 1 unit Accuprime HiFi taq, 1 mL of 0¢0025 mg/mL BSA,
and 400 nM of forward and reverse primer. The reaction conditions
were 95°C for 2 minutes, followed by 40 cycles of 95°C for 30 seconds,
60°C for 30 seconds and 68°C for 1 minute, with a final extension of
68°C for 10 minutes. PCR products were quantified using picogreen
on a microplate reader. Amplicons were pooled, prepared for
sequencing using Kappa HyperPrep Kits (Roche, Indianapolis, IN) and
sequenced on a single MiSeq (Illumina, San Diego, CA) run using
250 bp paired-end chemistry at the UNC High Throughput Sequenc-
ing Facility.
Sequencing data was analyzed using SeekDeep v2¢6¢5 using
default parameters [28]. Briefly, data were demultiplexed using the
dhps primers and a dual barcoding scheme, and final haplotypes for
each sample were determined by removing low per-base quality
scores and low frequency mismatches. Final haplotypes were further
filtered by removing haplotypes with <2,000 reads within samples.
We then selected DNA from samples containing a single variant con-
sistent with a wild-type or A581G mutant parasite for SHERLOCK
SNV testing. Mixed infections were excluded. Wild-type parasiteswere stratified by sampling location and selected for SHERLOCK test-
ing using a random number generator (Excel, Microsoft, Seattle, WA).2.11. Dhps SNV detection by SHERLOCK
All dhps SNV-detection SHERLOCK assays were performed in trip-
licate using the conditions described above. Positive SHERLOCK calls
were made if background-subtracted fluorescence was positive. Clin-
ical sensitivity, clinical specificity, and Cohen’s Kappa coefficient
were calculated using deep sequencing calls as the gold standard.2.12. Statistical analysis
Statistical analyses were performed in Prism (RRID:SCR_002798,
GraphPad, San Diego, CA) and R (R Core Team, Vienna, Austria). Com-
parisons were made using the t-test for continuous variables. Probit
analysis was used to determine the 95% limit of detection and 95%
confidence intervals for each SHERLOCK assay. Samples were not ran-
domized and experimenters were not blinded in conducting these
experiments.3. Results
We translated SHERLOCK to malaria by designing and screening
candidate RPA primers and crRNAs, optimizing assay conditions, and
validating them on clinical and mosquito samples collected in diverse
sites (Figure 1). Assay development included the design and testing of
two broad categories of RPA primers and crRNAs. The first design tar-
geted conserved and variable regions of the Plasmodium 18S rRNA
gene and enabled detection and species identification of Plasmodium
parasites in clinical samples and mosquitoes. The second design
included engineered crRNA-target mismatches to enable detection of
the P. falciparum A581G mutation associated with resistance to sulfa-
doxine (Figure 2). A range of reaction parameters were tested during
pilot testing. While we were unable to replicate the “one-pot” reac-
tion approach (combining RPA, IVT, and Cas13a detection) previously
described for viral targets,[10] we achieved best performance using a
two-step reaction format (RPA followed by IVT and Cas13a detection)
and 10-50-fold higher crRNA concentrations than those originally
described by Gootenberg et al [9].
3.1. Plasmodium SHERLOCK achieves robust analytical sensitivity and
specificity
Our SHERLOCK assays demonstrated attomolar analytical sensitiv-
ity for Plasmodium DNA, equivalent to 95% lower limits of detection
(LODs) of 2¢5-18¢8 parasite genomes per reaction (4¢2-31¢3 aM;
Figure 3, Table 1) for all three assays. Using only 1 mL of initial DNA
input, this is roughly equivalent to 2¢5-18¢8 parasites/mL. These sen-
sitivities approach those of commonly deployed malaria real-time
PCR assays,[3] which achieved 0¢3-2¢5 parasites/mL analytical sensi-
tivities during head-to-head testing in one controlled setting [29].
The pan-Plasmodium and P. falciparum SHERLOCK assays achieved
superior LODs compared to P. vivax, but all three assays achieved
LODs well below those detected by commonly used malaria RDTs
(Table 1).
To test the specificity of our SHERLOCK assays against different
Plasmodium species, we conducted assays using high concentration
18S rRNA plasmid DNA or gDNA from all five human-infecting Plas-
modium species (Figure 4). The pan-Plasmodium SHERLOCK assay
detected all five Plasmodium species, while the P. falciparum SHER-
LOCK assay only displayed activity against P. falciparum gDNA. The P.
vivax SHERLOCK assay detected P. vivax 18S rRNA plasmid DNA, but
also demonstrated low-level cross-reactivity for P. knowlesi gDNA.
Fig. 3. Analytical sensitivity of Plasmodium spp. SHERLOCK assays. (a) Pan-Plasmodium assay vs. P. falciparum strain 3D7 gDNA (b) Pan-Plasmodium assay vs. P. vivax 18S rRNA plas-
mid DNA (c) P. falciparum assay vs. P. falciparum strain 3D7 gDNA (d) P. vivax assay vs. P. vivax 18S rRNA plasmid DNA. N = 3 technical replicates, n = 1 biological replicate. Unpaired
student’s T test vs. NTC, § SEM. Abbreviations: NTC, no template control.
Table 1
95% lower limits of detection (LOD) for Plasmodium spp. SHERLOCK assays. Input is 1mL of DNA template per reaction.
Parasites/mL (replicates detected / replicates tested)
SHERLOCK Assay LOD (95% CI) 105 104 103 102 20 15 10 5 2¢5 1¢25
Pan-Plasmodium 2¢5 (1¢9-21¢3) 3/3 3/3 3/3 3/3 - - 20/20 20/20 19/20 14/20
P. falciparum 6¢8 (5¢3-11¢6) 3/3 3/3 3/3 3/3 - - 20/20 17/20 9/20 8/20
P. vivax 18¢8 (13¢3-146¢3) 3/3 3/3 3/3 3/3 20/20 20/20 10/20 19/20 - -
Fig. 4. (a) Pan-Plasmodium SHERLOCK assay can detect all five Plasmodium species in humans, while (b) P. falciparum, and (c) P. vivax SHERLOCK assays can differentiate between
Plasmodium species. Input for all species was the equivalent of 100,000 parasites/mL as either species-specific 18S plasmid or gDNA n (P. knowlesi only). N = 3 technical replicates,
n = 1 biological replicate. Unpaired student’s T test vs. NTC, § SEM. Abbreviations: NTC, no template control.
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mosquitoes
Our SHERLOCK assays successfully detected and differentiated the
four most common Plasmodium spp. known to cause human malaria
from clinical samples across a range of parasite densities. When
applied to a panel of real-time PCR-positive clinical isolates from theDRC and Thailand, the species-specific P. falciparum and P. vivax
assays demonstrated complete clinical specificity (Figure 5). When
applied to a larger panel of 62 PCR-positive and 50 PCR-negative
samples from the DRC and Uganda, the P. falciparum SHERLOCK
assay’s sensitivity and specificity were 94% and 94%, respectively,
compared to real-time PCR (Supplementary Figure 4, Supplementary
Table 5). The four PCR-positive/SHERLOCK-negative samples had
Fig. 5. (a) Pan-Plasmodium, (b) P. falciparum, and (c) P. vivax SHERLOCK assays successfully detected and differentiated Plasmodium infections in diverse clinical isolates. (d) P. falci-
parum SHERLOCK assay detected both the oocyst and sporozoite stages of DNA extracted from infected mosquitos. Pf gDNA in the mosquito assay was 100,000 parasites/mL. Parasite
densities were determined by qPCR for Pf, Pm, and Po and by microscopy for Pv. N = 3 technical replicates, n = 1 biological replicate. Unpaired student’s T test vs. NTC, § SEM. Abbre-
viations: Pf, P. falciparum; Pv, P. vivax; Pm, P. malariae; Po, P. ovale; NTC, no template control; gDNA, genomic DNA; Sub, subject.
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error or stochastic amplification failure during the initial assay.
When SHERLOCK was performed in singleton, Cohen’s kappa was
0¢87, consistent with excellent agreement between methods.
The P. falciparum SHERLOCK assay also performed well when
applied to DNA extracted from pooled, infected mosquitoes (n=4)
(Figure 5). In all cases, the P. falciparum SHERLOCK assay was able to
detect the presence of parasites, including both the sporozoite and
oocyst stages within the sporogonic life cycle.
3.3. SHERLOCK can be used to detect SNVs associated with antimalarial
drug resistance
Amplicon-based deep sequencing was performed to distinguish
wild-type and A581G mutant dhps P. falciparum infections in 185
samples from the DRC and Uganda collected from patients with
symptomatic malaria. The A581G mutation is associated with high-
level resistance to sulfadoxine. The median read count per sample
was 81,775. After filtering, only two variants were observed across all
samples, corresponding to wild-type and A581G mutant dhps. Forty-
three samples that were confirmed to be mono-infections bearing
only wild-type or A581G mutant dhps mutations were selected for
testing by SHERLOCK.
When applied to 22 wild-type and 21 A581G mutant dhps sam-
ples from Uganda, the sensitivity and specificity of the P. falciparum
dhps SHERLOCK assay were 73% and 100%, respectively, using dhps
deep sequencing calls as the gold standard. Cohen’s kappa was 0¢72,
consistent with good agreement between SHERLOCK and amplicon-
based deep sequencing. When restricted to field samples with para-
site densities of 420 parasites/mL, the dhps SHERLOCK assay’s clini-
cal sensitivity and specificity were 100% and 100%, respectively.Among these higher parasite density samples, Cohen’s kappa was
1.0, consistent with perfect agreement between the dhps SHERLOCK
assay and amplicon-based deep sequencing in these samples with
higher parasite densities.4. Discussion
We describe a suite of novel SHERLOCK malaria assays and high-
light the versatility of CRISPR-based diagnostics for a range of infec-
tious disease applications. The new assays achieved robust clinical
sensitivity and specificity when applied to well-characterized clinical
samples and were easily adapted for parasite detection in mosquitoes
and for drug-resistance genotyping. New diagnostics that can be used
to detect, identify species, and genotype P. falciparum infections rap-
idly and reliably are especially needed in sub-Saharan Africa, where
94% of malaria deaths occur (https://www.who.int/publications/i/
item/9789241565721).
These SHERLOCK malaria assays outperform HRP2-based RDTs,
the predominant malaria diagnostic modality deployed throughout
Africa, and achieve similar performance to recently developed ultra-
sensitive HRP2-based RDTs, which have achieved clinical sensitivities
of roughly 3 parasites/mL [30,31]. Increasing reports of P. falciparum
with deletion mutations of the histidine rich 2 and/or 3 (pfhrp2/3)
genes raise concerns about reliance on HRP2 as the primary diagnos-
tic target for RDTs [2]. RDTs that detect alternative antigens such as
pLDH are available, but they are less sensitive and less heat-stable
than HRP2-based RDTs. Thus, there is a need for novel malaria diag-
nostics that detect other targets. While both SHERLOCK and other
CRISPR-based diagnostic assays currently in development need addi-
tional optimization prior to field deployment, we demonstrate that
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ing avenue for malaria diagnostic development.
The analytical and clinical sensitivity of these SHERLOCK malaria
assays approached that of commonly used real-time PCR assays, but
the ability to conduct SHERLOCK without thermocycling allows for
reduced laboratory infrastructure requirements and enables simpli-
fied isothermal approaches. More recently developed “ultrasensitive
PCR” assays that target RNA and/or multicopy genes have achieved
analytical sensitivities as low as 0¢02 parasites/mL, but their use in
low-resource laboratory settings is limited by the need to protect
against RNA degradation and/or the requirement for large-volume
samples [32,33]. LAMP is an alternative nucleic acid detection
method that has been used for malaria diagnosis in field settings
with similar sensitivity and specificity to SHERLOCK [34]. LAMP
shows promise as a field-deployable molecular diagnostic, but its use
for bespoke applications has been hampered by the complexity of
target selection and primer design. CRISPR-based diagnostic
approaches like SHERLOCK are an emerging technology that can be
rapidly adapted in response to malaria’s evolving epidemiology [35].
Species discrimination was excellent across Plasmodium spp.
SHERLOCK assays, with the exception of the P. vivax SHERLOCK assay
that demonstrated cross-reactivity with P. knowlesi. The P. vivax
spacer and the analogous region on P. knowlesi differ by four nucleoti-
des, so this cross-reactivity was unexpected. One explanation is that
these nucleotides are towards the 3’ end of the crRNA spacer (posi-
tions 20, 26, 27 in the 28), which have been shown to have a smaller
influence on crRNA binding efficiency [9]. Another explanation is
unappreciated homology between P. vivax and P. knowlesi spacer
binding sites in the setting of incomplete understanding of P. knowle-
si’s genetic diversity. These findings highlight the importance of using
high-quality genomic data when designing target sequences for
CRISPR-based diagnostics and consideration of sequence variability
within targets. Future SHERLOCK assays will be strengthened by
efforts to improve our understanding of parasite genomic diversity
[36,37].
Our novel SNV detection SHERLOCK assay for the dhps 581G vari-
ant in P. falciparum represents one of the first uses of SHERLOCK to
detect SNVs in clinical isolates outside of its original description
[9,10]. We chose to develop a SHERLOCK SNV detection assay for
Plasmodium dhps variants due to their public health importance in
the prevention of malaria during pregnancy. Variants in the dhps
gene can confer resistance to sulfadoxine, which is used in combina-
tion with pyrimethamine (SP) as the primary antimalarial drug for
intermittent preventive treatment in pregnancy (IPTp) to prevent
malaria in pregnancy throughout much of sub-Saharan Africa [38].
Our dhps SHERLOCK assays demonstrated parasite-density depen-
dent sensitivity and perfect specificity when compared to amplicon-
based deep sequencing. When applied to a wide range of parasite
inputs, the assay only produced false-negative results in samples
with low parasite densities (6/7 samples with 319 parasites/mL
sample input). While the SNV detection assay is concentration
dependent, it performed well at parasite densities typically associ-
ated with clinically significant malaria [39]. In future, mixed infec-
tions involving both wild-type and 581G mutant strains could be
identified by pairing the 581G-specific assay described here with a
wild-type-specific assay in a multiplexed format. SHERLOCK’s SNV
detection capabilities are a promising tool for malaria control pro-
grams in low-resource settings where sequencing facilities are not
available to support surveillance. For example, high prevalence of
resistance-associated dhps variants detected by SHERLOCK could trig-
ger deployment of alternative drug regimens for IPTp in affected
regions.
Our SHERLOCK assays are now one of two published CRISPR-
based diagnostic modalities for Plasmodium detection; in a recently
published manuscript, Lee et. al. describe a suite of highly sensitive
and specific assays for P. falciparum, P. vivax, P. malariae, and P. ovalespp. [40]. These assays employ a detection approach most similar to
the DNA endonuclease-targeted CRISPR trans reporter (DETECTR)
methodology, which uses the DNA endonuclease Cas12 [41]. While
our methods differ in this regard, both approaches highlight the
potential uses for SHERLOCK and other CRISPR-based diagnostics for
malaria diagnosis, research, and drug resistance surveillance.
The assays described by Lee et al have several advantages and dis-
advantages compared to our assays. First, the analytical sensitivity
achieved by Lee et. al. is superior. The 95% lower LODs of their P. falci-
parum and P. vivax assays were 0¢36 (0¢23-1¢0) and 1¢2 (0¢52-6¢2)
parasites/mL compared to our 95% lower LODs of 6¢8 (5¢3-11¢6) and
18¢8 (13¢3-146¢3), respectively. One explanation for this improved
performance is that Lee et al. chose gene targets that are present in
higher copy numbers: Pfr364 subtelomeric repeat DNA for P. falcipa-
rum (41 copies) and mitochondrial DNA for P. vivax (up to 20 copies)
vs. 18s rRNA in our assays (~6 copies). While the use of 18S rRNA tar-
gets reduces assay sensitivity, it provides opportunities for stream-
lined, multiplexed assays that employ a single, shared RPA primer set
targeting regions that are conserved across Plasmodium species and
bespoke crRNAs for species identification. Second, Lee et al. describe
streamlined approaches to nucleic acid extraction and reaction set-
up that are better suited for field use. These advances make it clear
that some of the challenges we encountered with our Cas13a-based
SHERLOCK approach can be overcome. Third, the clinical perfor-
mance of the assays described by Lee et al. is not yet defined. They
conducted validation experiments using a panel of simulated samples
derived from cultured parasites and a small number of serum sam-
ples, whereas we validated our assays on dried blood spot samples
collected in malaria endemic countries, including a large panel of 112
samples for our P. falciparum assay. This type of clinical validation is
important because samples collected under field conditions is neces-
sary to define real-world assay performance, both in terms of sample
preparation/integrity and parasite genetic diversity. Genetic diversity
of sites targeted by these assays can only be partly deduced from
publicly available sequencing data, especially in the case of non-falci-
parum species like P. ovale and P. malariae that are not well repre-
sented in existing databases. Despite these differences, the
performance of both sets of CRISPR-based diagnostic assays demon-
strates that they can detect parasite concentrations well below what
is expected in clinical malaria and supports future studies to adapt
and validate these assays for use in research and clinical settings.
We chose LwCas13a-based detection over a Cas12a-based
approach to take advantage of Cas13a’s minimal protospacer-adja-
cent motif (PAM) site nucleotide requirements compared to Cas12a.
LwCas13a requires only H (not G) adjacent to the spacer region,
which makes guide design and SNV detection for LwCas13a easier
than for Cas12a, which has a PAM requirement of “TTTN” [41,42].
Additionally, multiplexing with SHERLOCK has been demonstrated
using Cas13a isolated frommultiple bacterial species, which have dif-
ferent collateral activities that can be used to activate different RNA
reporters, enabling multiplexed assays [10]. These properties of
Cas13a provide opportunities for further assay development, includ-
ing translation of our malaria SHERLOCK assays into a single, multi-
plexed assay that enables species identification of multiple
Plasmodium species and drug-resistance SNVs in a single reaction.
We experienced success using SHERLOCK to detect Plasmodium spp.
and drug-resistance variants; however, several limitations must be
overcome for successful translation of SHERLOCK from the laboratory
to the field. First, we could not achieve the sub-attomolar limits of
detection or “one-pot” reaction conditions previously described for
viral targets [10]. We also observed that our assays performed best
using higher crRNA concentrations than those originally described
[9]. Though this may reflect differences in crRNA synthesis or lot-to-
lot variation in other reagents, we observed improved reaction per-
formance with higher crRNA concentrations across multiple experi-
ments.
Fig. 6. The dhps SHERLOCK assay detects P. falciparum parasites with (a) mutant (581G) but not (b) wild-type (A581) alleles. Parasite densities were determined by qPCR. N = 3 tech-
nical replicates, n = 1 biological replicate,§ SEM. Mutant (Mut) andWT gDNA standard inputs were 100,000 parasites/mL.
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not trivial. In a reaction volume of 25 mL used for 96-well plates and
using fluorescent output, the cost was roughly equivalent to PCR at
over $2¢00 of reagent costs per technical replicate, plus upfront costs
of crRNA optimization and synthesis and the need for a fluorescence
plate-reader. These costs can be reduced for assays brought to scale
but are an important consideration during assay design. Finally,
SHERLOCK requires multiple reagents, custom crRNAs, and Cas13a.
Recent progress has been made to reduce its complexity and make
these assays more easily accessible [43]. Indeed, the approach
described by Lee et. al includes a streamlined workflow from sample
collection to Cas12a-based detection; including an optimized nucleic
acid extraction step, one-pot lyophilized reaction, reduced reaction
time, and a handheld fluorometer and lateral-flow readout. Other
groups have sought to replace RPA preamplification with LAMP, or
eliminate it altogether in the case of one Cas13a-based SARS-CoV-2
diagnostic (https://doi.org/10.1101/2020.12.14.20247874)[44]. While
these advances confirm rapid improvements in CRISPR-based assay
performance and feasibility, implementation of SHERLOCK as a
point-of-care molecular diagnostic will require further streamlining
including the development of commercially-available mastermixes
and the combination of nucleic acid extraction, Cas effector activa-
tion, and signal readout into a single device.
While these limitations must be overcome before immediate field
applications, SHERLOCK is a promising technology with multiple
potential uses in malaria diagnosis, research, and drug resistance sur-
veillance. In particular, our SNV detection SHERLOCK assays demon-
strate applications beyond infectious disease diagnosis and includegenotyping pathogens at the nucleotide level. With further optimiza-
tion, our SNV detection assays could facilitate drug resistance surveil-
lance for malaria control programs without the need for PCR or
sequencing. Additionally, our pilot application of SHERLOCK to detect
P. falciparum in infected mosquitoes demonstrates potential beyond
clinical diagnostics and other uses for research in low malaria trans-
mission or near elimination settings. Continued development of new
Cas effectors, streamlined workflows, and point-of-care read-outs
will open new opportunities for CRISPR diagnostics in clinical, sur-
veillance, and research applications. These novel malaria SHERLOCK
assays confirm the promise of CRISPR-based diagnostics for diverse
applications and in resource-limited settings (Fig. 6).
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